Symptoms last for two years for some; Inflammatory protein samples can give prolonged COVID symptoms

A medical worker prepares a syringe with a dose of Johnson and Johnson coronavirus (COVID-19) vaccine during a visit to the Chicago Vaccination Center on April 6, 2021, by Vice President Kamala Harris in Chicago, Illinois, USA. The photo was taken on April 6, 2021. REUTERS / Carlos Barria

Sign up now for FREE unlimited access to Reuters.com

May 12 (Reuters) – The following is a summary of recent studies on COVID-19. They include studies that require further study to confirm the findings and have not yet been confirmed by examination.

Symptoms of Covid-19 still persist after two years

A new study shows that half of COVID-19 patients discharged from a Chinese hospital in early 2020 have another symptom two years later.

Sign up now for FREE unlimited access to Reuters.com

Overall, 2,469 COVID-19 survivors who participated in the study improved their physical and mental health over time, despite the initial severity of the disease. Almost 90% of those employed returned to work within two years. Researchers in The Lancet Respiratory Diseases on Wednesday found that the health status of two-year-old survivors was “surprisingly” lower than the general population’s health, and that the symptoms that followed were “significantly higher.” According to the report, at least 55% had a COVID-19 effect in two years. Fatigue or muscle weakness were the most common symptoms during the study. Patients who require mechanical ventilation for severe disease have higher rates of lung damage for two years.

“Our findings show that although some of the hospitalized COVID-19 survivors cleared their initial infection, it will take more than two years to fully recover from COVID-19,” the researchers said.

Protein “samples” can help classify long-term COVID patients

New discoveries suggest that samples of inflammatory proteins in the blood of people with chronic COVID may one day help with individual treatment.

The researchers studied 55 people with COVID-19 who had a mild case of COVID-19 and found that about two-thirds had high levels of inflammatory proteins in their blood, and that ongoing inflammation could occur in people with the highest levels. The burden of prolonged COVID symptoms. “While previous studies have shown high levels of such proteins in patients with chronic COVID, we provide the first evidence that more than half have a signature or sample, while others do not,” the researchers said in a statement before review at the Bio Archive on Tuesday. .

“At least two different inflammatory proteins have been identified,” said Troy Thorgerson, research director at the Allen Institute of Immunology in Seattle. According to Torgerson, the presence of these schemes indicates that the immune system is activated in certain ways that can respond to treatment with current anti-inflammatory or immunosuppressive drugs, Torgerson said. “Measuring these proteins in the blood can help identify long-term COVID patients who may be good candidates for treatment studies using these medications or future treatments.”

Interference of vaccinated persons may impair the effectiveness of vaccines

Increased contact between vaccinated people may lead to the false impression that COVID-19 vaccines are not working, the researchers warn.

Some studies suggest that vaccinated people become infected faster than unvaccinated people, but these studies may contain statistical errors, especially if they do not take into account different patterns of interaction between vaccinated and unvaccinated people, says Corrin Bodner. Michael’s Hospital, Unity Health Toronto. Using computer models to simulate epidemics with a vaccine that protects against infection and infection, his team identified the conditions that would create the “perfect storm to observe the negative effects of the vaccine, even when the vaccine is effective,” Bodner said. Effective vaccines may be ineffective when vaccinated people have more contact with each other than those who have not been vaccinated, when the benefits of the vaccine are reduced but not eliminated (as in the new SARS-CoV-2 variants) or when efficacy is measured during an epidemic. According to a report published before the review on the medRxiv website, it is growing (for example, when a new version appears).

The simulations do not prove that the efficacy of the Omicron variant vaccine has been adversely affected. But they said that “even if vaccines do work, increased contact between vaccinated people can lead to vaccine failure.”

Click to see a Reuters chart about current vaccines.

Sign up now for FREE unlimited access to Reuters.com

Nancy Lapid’s report; Edited by Bill Berkrot

Our Standards: Thomson Reuters Trust Principles.

.

Leave a Comment

Your email address will not be published.